Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05136365
Other study ID # SHXD2021CR2103B
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 28, 2021
Est. completion date August 30, 2022

Study information

Verified date April 2024
Source Shanghai Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang Hai Mental Health Center. Following a screening period, subjects who meet the entry criteria will be treated with 450mg Xiongdan Wan pills three times daily for 8 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 30, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Meets the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD): a single or recurrent episode without psychotic features. Codes are as follows: F32.0, F32.1, F32.2, F33.0, F33.1, F33.2. 2. Outpatients. 3. Male or female subjects aged 18-65 years. 4. HAMD-17 score of the baseline period and screening period is 18-24. 5. Women of childbearing potential must be willing to use acceptable methods of contraception throughout the study period and the following one month. 6. The patient fully understands and signs the informed consent form. Exclusion Criteria: 1. Patient has survived a suicide attempt or has acute suicidal tendencies (HAMD-17 Item3 =3). 2. Comorbidity according to DSM-IV-TR, axis-I except for major depressive disorder. 3. HAMD-17 reduction ratio =25% within one week from the screening to the baseline period. 4. Depressive episode secondary to psychiatric illness or somatic disease. 5. Serious and unstable diseases such as cerebrovascular disease; liver and kidney disease; disease of internal secretion (abnormal thyroid function); hemopathy; seizures, or other encephalopathies. 6. History of alcohol or drug abuse over the last 6 months. 7. Allergic history to Xiongdan Wan, or serious drug allergic history. 8. Pregnant or lactating women and women of childbearing potential throughout the study period; men who have the desire of fertility within six months. 9. Clinically significant changes in ECG or laboratory tests, including >1.5 times the upper limit of normal liver function; over the limit of normal renal function and blood sugar; abnormal cardiac troponins; obvious abnormity in the thyroid function. 10. Treatment with modified electroconvulsive therapy (MECT) or repetitive transcranial magnetic stimulation (rTMS) in the past three months. 11. Treatment with a systematic psychological treatment in the past three months.

Study Design


Intervention

Drug:
Xiongdan Wan
Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score compared with baseline at the end of study. The main objective is to explore whether Xiongdan Wan improve the MDD symptoms after 8 weeks of treatment, and investigators assess the scale at week 1, 2, 4, 8. 8 weeks
Secondary Effective treatment Montgomery-Asberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale (HAMD-17)reduction ratio =50% reductive ratio [(Baseline score- Endpoint score)/Baseline score]×100% 8 weeks
Secondary Clinical remission rate Patients in remission at the end of the study will be summarized, Montgomery-Asberg Depression Rating Scale (MADRS) score =12 or Hamilton Depression Rating Scale (HAMD-17)=7. 8 weeks
Secondary The Montgomery-Asberg Depression Rating Scale (MADRS) reduction ratio MADRS reduction ratio is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8. 8 weeks
Secondary The Hamilton Depression Rating Scale (HAMD-17) reduction ratio HAMD-17 reduction ratio is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8. 8 weeks
Secondary Change in the total score of the Hamilton Anxiety Scale(HAMA) The change of HAMA is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8. 8 weeks
Secondary Change in total score of the Clinical Global Impression scale(CGI) The change of CGI is used to evaluate the effectiveness of the treatment and investigators assess the scale at week 1, 2, 4, 8. 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4